| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/03/2004 | US20040106682 Novel benzylideneamino guanidines and their uses as ligands to the melnocortin receptors |
| 06/03/2004 | US20040106664 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| 06/03/2004 | US20040106659 hydantoin, oxazoledione and thiazoledione (or dithiione) derivatives; e.g., 5-[1-(Biphenyl-4-yloxy)-ethyl]-5-methyl-imidazolidine-2,4-dione |
| 06/03/2004 | US20040106656 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 06/03/2004 | US20040106654 Inhibitors of copper-containing amine oxidases |
| 06/03/2004 | US20040106652 such as (2S)-3,3-dimethyl-1-[2-(5-phenylpentanoyl) pyrrolidinyl]pentane-1,2-dione which has affinity for immunophilin; for treatment of neurological disorders/neurodegenerative diseases; nerve growth factors; FK binding proteins |
| 06/03/2004 | US20040106650 4-Pyrrolidino-phenyl-benzyl ether derivatives |
| 06/03/2004 | US20040106646 Visual function disorder improving agents |
| 06/03/2004 | US20040106645 Antagonists of melanin concentrating hormone receptor |
| 06/03/2004 | US20040106643 e.g., (1S,2R,3R,5R)-3-(3,4-Dichlorophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid ethyl ester; |
| 06/03/2004 | US20040106641 e.g., N-(4-pyridylmethyl)-1-cyclopropylmethyl-7-azaindole-3-carboxylic acid amide |
| 06/03/2004 | US20040106640 Aryl ether substituted imidazoquinolines |
| 06/03/2004 | US20040106636 said analgesic contains an opioid moiety of chemically modified morphine that binds to and activates an mu opioid receptor (MOR), and a tachykinin peptide substance P (SP) peptide fragment moiety that binds to and activates an SPR |
| 06/03/2004 | US20040106635 Spiroisoquinoline compound, a method for preparing the same and an intermediate thereof |
| 06/03/2004 | US20040106628 CX3CR1 receptor antagonists useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease and pain |
| 06/03/2004 | US20040106625 Therapeutic agents useful for treating pain |
| 06/03/2004 | US20040106624 useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis |
| 06/03/2004 | US20040106621 3-Heterocyclic benzylamide derivatives as potassium channel openers |
| 06/03/2004 | US20040106620 5-Substituted-2-arylpyrazines |
| 06/03/2004 | US20040106616 To treat one or more conditions responsive to capsaicin receptor modulation, such as pain, itch, urinary incontinence, cough, hiccup, and/or obesity |
| 06/03/2004 | US20040106615 For treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplant |
| 06/03/2004 | US20040106614 Useful for the treatment of psychiatric and neurological disorders, as well as other diseases involving cannabinoid-CB1 neurotransmission |
| 06/03/2004 | US20040106610 Antagonize pharmacological actions of the endogenous neuropeptide tachykinins known as neurokinins |
| 06/03/2004 | US20040106607 New compounds |
| 06/03/2004 | US20040106604 Novel pyrrole derivatives as pharmaceutical agents |
| 06/03/2004 | US20040106603 Diazabicyclic compounds useful in the treatment of CNS and other disorders |
| 06/03/2004 | US20040106576 Derivatives of venlafaxine and methods of preparing and using the same |
| 06/03/2004 | US20040106575 2-Alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| 06/03/2004 | US20040106574 4-substituted with a imidazo[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl ring |
| 06/03/2004 | US20040106565 Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells |
| 06/03/2004 | US20040106560 such as N1-L-Arginylspermidine for protecting from damage from extended ischemic/hypoxic events |
| 06/03/2004 | US20040106558 Hydroxamate-containing cysteine and serine protease inhibitors |
| 06/03/2004 | US20040106556 solvent extraction; amyloid precursor proteins |
| 06/03/2004 | US20040106554 polypeptide analogs of myelin basic protein for treatment of multiple sclerosis |
| 06/03/2004 | US20040106539 Agents for the treatment of viral infections |
| 06/03/2004 | US20040106197 Central nerve system precursor cells inducing synaptogenic neurons in spinal cord |
| 06/03/2004 | US20040106196 Systems and methods for treating patients with processed lipoaspirate cells |
| 06/03/2004 | US20040106155 Method for kidney disease treatment by drug intervention |
| 06/03/2004 | US20040106124 Identifying genotype for depressive episodes and modifying administration of antidepressants and adrenergic stimulants |
| 06/03/2004 | US20040105887 Controlled release oxycodone compositions |
| 06/03/2004 | US20040105841 Interferons, uses and compositions related thereto |
| 06/03/2004 | US20040104142 Blister package for topiramate tablets |
| 06/03/2004 | DE10254875A1 Phenylsulfoxid und -sulfon-Derivate Phenylsulfoxide and sulfone derivatives |
| 06/03/2004 | CA2518917A1 Pyridazinone derivatives as cdk2-inhibitors |
| 06/03/2004 | CA2506850A1 Compounds and methods for increasing neurogenesis |
| 06/03/2004 | CA2506565A1 Diazinopyrimidines |
| 06/03/2004 | CA2506297A1 Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors |
| 06/03/2004 | CA2506050A1 Methods, nucleic acid constructs and cells for treating neurodegenerative disorders |
| 06/03/2004 | CA2506022A1 Pyridazinone derivatives as gsk-3beta inhibitors |
| 06/03/2004 | CA2503316A1 Method and compositions for temporarily incapacitating subjects |
| 06/03/2004 | CA2503312A1 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs |
| 06/03/2004 | CA2499133A1 Pyrazine compounds as crf modulators |
| 06/02/2004 | EP1424392A1 Novel secretory proteins and dna thereof |
| 06/02/2004 | EP1424336A1 1,3-benzothiazinone derivatives and use thereof |
| 06/02/2004 | EP1424335A1 Indole derivatives |
| 06/02/2004 | EP1424333A1 Halothenoyl-cyclopropane-1-carboxylic acid derivatives |
| 06/02/2004 | EP1424330A1 Activator for peroxisome proliferator-responsive receptor delta |
| 06/02/2004 | EP1424325A1 Indole derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 06/02/2004 | EP1424101A2 Use of a leukotriene C4 and D4 receptor antagonist for the preparation of a medicament for treating or preventing brain inflammation and sepsis |
| 06/02/2004 | EP1424080A1 Gnrh agonist combination drugs |
| 06/02/2004 | EP1424071A1 Perfume compositions |
| 06/02/2004 | EP1423697A2 Secreted proteins |
| 06/02/2004 | EP1423537A2 Compositions and methods for the prevention and treatment of huntington's disease |
| 06/02/2004 | EP1423511A2 Nucleic-acid associated proteins |
| 06/02/2004 | EP1423509A2 Differentiation of neural stem cells and therapeutic use thereof |
| 06/02/2004 | EP1423436A2 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids |
| 06/02/2004 | EP1423422A2 A caspase- 8 binding protein, its preparation and use |
| 06/02/2004 | EP1423415A2 Intracellular signaling molecules |
| 06/02/2004 | EP1423413A1 Peptidic compounds selectively binding to p-selectin |
| 06/02/2004 | EP1423411A2 Prodrugs of excitatory amino acids |
| 06/02/2004 | EP1423406A2 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 06/02/2004 | EP1423404A2 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/02/2004 | EP1423392A1 Derivatives of morphine-like opioid compounds |
| 06/02/2004 | EP1423390A2 Purine inhibitors of phosphodiesterase (pde) 7 |
| 06/02/2004 | EP1423388A2 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |
| 06/02/2004 | EP1423384A1 Pyridine derivatives as raf kinase inhibitors |
| 06/02/2004 | EP1423382A2 Pyrazole-derived kinase inhibitors and uses thereof |
| 06/02/2004 | EP1423380A1 Pyrazole-derived kinase inhibitors and uses thereof |
| 06/02/2004 | EP1423364A1 Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 06/02/2004 | EP1423168A2 Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use |
| 06/02/2004 | EP1423167A1 Method for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo- and hydroxy-substituted hydrocarbons |
| 06/02/2004 | EP1423146A1 Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain |
| 06/02/2004 | EP1423145A1 Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain |
| 06/02/2004 | EP1423139A2 New use of artemin, a member of the gdnf ligand family |
| 06/02/2004 | EP1423132A2 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 06/02/2004 | EP1423128A2 Methods for the treatment of chronic pain anc compositions therefor |
| 06/02/2004 | EP1423127A1 Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
| 06/02/2004 | EP1423124A2 Lyophilized formulation comprising olanzapine |
| 06/02/2004 | EP1423123A1 Tetracyclic indole derivatives as 5-ht receptor ligands |
| 06/02/2004 | EP1423120A1 2h-phthalazin-1-ones and methods for use thereof |
| 06/02/2004 | EP1423119A1 Heterobicycles fkbp-ligands |
| 06/02/2004 | EP1423117A1 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors |
| 06/02/2004 | EP1423116A1 Method of treating alcoholism or alcohol abuse |
| 06/02/2004 | EP1423114A2 Method and compositions for treating migraines |
| 06/02/2004 | EP1423112A1 A combination of quetiapine and zolmitriptan |
| 06/02/2004 | EP1423107A2 Fatty alcohol drug conjugates |
| 06/02/2004 | EP1423106A1 Arylsulfonyl derivatives with 5-ht 6 receptor affinity |
| 06/02/2004 | EP1423104A1 Combination therapy for the treatment of neurological disorders |
| 06/02/2004 | EP1423103A2 Compositions and methods for modulation of darpp-32 phosphorylation |
| 06/02/2004 | EP1423099A1 A new extended release oral dosage form |